Rhythm Pharmaceuticals Inc
$ 87.87
-0.51%
01 Jun - close price
- Market Cap 6,027,318,000 USD
- Current Price $ 87.87
- High / Low $ 89.05 / 86.00
- Stock P/E N/A
- Book Value 2.07
- EPS -3.13
- Next Earning Report 2026-08-04
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.30 %
- ROE -1.01 %
- 52 Week High 122.20
- 52 Week Low 60.70
About
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of rare genetic diseases of obesity. The company is headquartered in Boston, Massachusetts.
Analyst Target Price
$138.20
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-05 | 2026-02-26 | 2025-11-04 | 2025-08-05 | 2025-05-07 | 2025-02-26 | 2024-11-05 | 2024-08-06 | 2024-05-07 | 2024-02-22 | 2023-11-07 | 2023-08-01 |
| Reported EPS | -0.83 | -0.73 | -0.82 | -0.75 | -0.81 | -0.72 | -0.73 | -0.55 | -2.35 | -0.7 | -0.76 | -0.82 |
| Estimated EPS | -0.86 | -0.8218 | -0.73 | -0.67 | -0.68 | -0.73 | -0.87 | -0.72 | -2.39 | -0.7 | -0.76 | -0.78 |
| Surprise | 0.03 | 0.0918 | -0.09 | -0.08 | -0.13 | 0.01 | 0.14 | 0.17 | 0.04 | 0 | 0 | -0.04 |
| Surprise Percentage | 3.4884% | 11.1706% | -12.3288% | -11.9403% | -19.1176% | 1.3699% | 16.092% | 23.6111% | 1.6736% | 0% | 0% | -5.1282% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-04 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.84 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: RYTM
2026-06-01 06:10:20
This article provides an overview of Rhythm Pharmaceuticals Inc.'s (RYTM) financial performance, focusing on its revenue breakdown, profitability margins, and a comparison with competitors CNTA and MIRM. RYTM boasts a high gross margin of 88.09%, although its operating and net margins are negative. The company has a market capitalization of $6.02 billion.
2026-05-30 00:39:11
The FDA has extended its review of Rhythm Pharmaceuticals' IMCIVREE for Acquired Hypothalamic Obesity until March 20, 2026, requesting additional efficacy data analyses but raising no new safety concerns. Despite a temporary dip in stock, analysts maintain a strong "Buy" rating with an average target of $140.18, signaling confidence in IMCIVREE's potential blockbuster status. The drug's strong clinical efficacy and "first-in-class" potential for an underserved market represent significant opportunities for the company.
2026-05-30 00:39:11
Rhythm Pharmaceuticals has introduced a new diagnostic algorithm for Bardet-Biedl syndrome (BBS) to enhance and expedite the clinical identification of this rare obesity disorder. This initiative aims to streamline diagnosis, thereby expanding the addressable patient pool for Rhythm's therapies and solidifying its position in the rare genetic obesity market. While improving patient identification, this strategy may also contribute to sustained high operational costs and attract larger competitors.
2026-05-29 17:38:58
This page provides a current overview of news and press releases related to RHYTHM PHARMACEUTICALS INC (NASDAQ:RYTM). It lists recent company announcements, including abstract acceptances for conferences, publication of a new diagnostic algorithm, and participation in investor conferences. The page also highlights past earnings reports, noting a Q1 earnings beat and Q4 revenue beat, alongside mixed Q3 and Q2 results.
2026-05-29 12:10:23
Rhythm Pharmaceuticals announced that seven abstracts, including four late-breaking ones, have been accepted for presentation at ENDO 2026. These presentations will cover new data on setmelanotide in Prader-Willi syndrome and acquired hypothalamic obesity, as well as bivamelagon in hypothalamic obesity. The company will also host its inaugural MOMENTUM meeting for experts ahead of the conference.
2026-05-29 12:10:23
Rhythm Pharmaceuticals (Nasdaq: RYTM) announced that seven abstracts, including four late-breaking, have been accepted for presentation at ENDO 2026. The presentations will cover setmelanotide and oral bivamelagon in Prader-Willi syndrome, acquired hypothalamic obesity, and Bardet-Biedl syndrome. Rhythm will also host its inaugural MOMENTUM meeting before ENDO, bringing together experts to discuss advancements in MC4R pathway diseases.
